Nuvectis Pharma, Inc. (NVCT)
NASDAQ: NVCT · IEX Real-Time Price · USD
6.57
-0.15 (-2.29%)
Jul 22, 2024, 9:55 AM EDT - Market open
Nuvectis Pharma Employees
Nuvectis Pharma had 13 employees as of December 31, 2023. The number of employees increased by 2 or 18.18% compared to the previous year.
Employees
13
Change (1Y)
2
Growth (1Y)
18.18%
Revenue / Employee
n/a
Profits / Employee
-$1,721,692
Market Cap
121.15M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 13 | 2 | 18.18% |
| Dec 31, 2022 | 11 | 3 | 37.50% |
| Dec 31, 2021 | 8 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| American Well | 1,104 |
| Agenus | 389 |
| Akoya Biosciences | 330 |
| Seer, Inc. | 147 |
| X4 Pharmaceuticals | 93 |
| Immunic | 77 |
| Athira Pharma | 67 |
| Werewolf Therapeutics | 47 |
NVCT News
- 2 months ago - Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference - GlobeNewsWire
- 2 months ago - Nuvectis Pharma, Inc. Reports First Quarter 2024 Financial Results and Business Highlights - GlobeNewsWire
- 3 months ago - Nuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines - GlobeNewsWire
- 4 months ago - Nuvectis Pharma Announces Upcoming Presentations at the 2024 American Association for Cancer Research Meeting - GlobeNewsWire
- 4 months ago - Nuvectis Pharma to Present at the 36th Annual Roth Conference - GlobeNewsWire
- 4 months ago - Nuvectis Pharma Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant ARID1a-Mutated Ovarian Cancer - GlobeNewsWire
- 4 months ago - Nuvectis Pharma, Inc. Reports Fiscal Year 2023 Financial Results and Business Highlights - GlobeNewsWire
- 5 months ago - Correction: Nuvectis Pharma Announces Participation at Upcoming Investor Conferences - GlobeNewsWire